Clinical study on the therapeutic effect of Juanbi Qianggu Formula combined with DMARDs on Rheumatoid Arthritis with liver and kidney deficiency

Phase 1

Recruiting

• Conditions: rheumatoid arthritis

• Registration Number: ITMCTR2100004848
• Lead Sponsor: Shanghai Guanghua Integrated traditional Chinese and Western Medicine Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Agree to participate in this study and sign an informed consent form;
2. Comply with the diagnostic criteria for rheumatoid arthritis stipulated in the classification standards of the American College of Rheumatology (ACR) in 1987 and the Chinese Medicine Industry Standards of the Peoples Republic of China Diagnosis and Efficacy Standards for Diseases and Symptoms of Traditional Chinese Medicine (ZY/T001.1-94) and Practical TCM Rheumatology (edited by Wang Chengde, Shen Pi'an, Hu Mengqi, People's Medical Publishing House, 2009) TCM Liver and Kidney Deficiency Type Kaibi Syndrome Differentiation Standard;
3. DAS28 score <=5.1;
4. TCM syndrome score >= 6 points.

Exclusion Criteria

1. Abnormal liver and kidney function;
2. Pregnant women or breastfeeding women, mental patients;
3. Patients with serious diseases such as heart, liver, brain, kidney and hematopoietic system;
4. Overlap other rheumatic diseases such as systemic lupus erythematosus, Sjogrens syndrome, severe knee osteoarthritis ;
5. Patients with advanced stage, severe joint deformity, and grade IV joint function;
6. Those who have received other study drugs 3 months before screening;
7. Those who are unable or unwilling to provide informed consent or unable to comply with the test requirements;
8. Researchers believe that it is not suitable for all subjects participating in this study.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
C-reactive protein;Cellular inflammatory factor;Blood routine;Erythrocyte sedimentation rate;